Rosuvastatin for Acute Systemic Crohn's disease: A mono-center randomized tria
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000002074
- Lead Sponsor
- Department of lower gastroenterology, Hyogo College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Not provided
(1) Patients treating hyperlipidemia with or without statins. (2) Patients of hypothyroidism (TSH elevates 1.5 times or higher than the normal limits) (3) Patient with high creatine kinase (3.0 times or higher than the normal limits) (4) Serum creatinine higher than 2.0 mg/dl (5) Liver dysfunction (ALT elevates 2.0 times or higher than the normal limits) (6) Past episode of malignancy and/or alcoholic or drug dependence (7) Women under or expecting pregnancy (8) Patients of acute inflammatic disease (9) Patients with having past episode of severe allergy (10) Patients have been enrolled for other clinical trial within past 3 months and/or enrolling other trial currently (11) Patients less than 20 y.o. and/or more than 65 y.o. (12) Patient who have determined by their physicians to have any reason of unqualified
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CDAI (Crohn's disease activity index) & IBDQ (a questionnaire for IBD patient) are evaluated at week 0,2,6,15(primary end-point),23(end).
- Secondary Outcome Measures
Name Time Method CRP, Total-cholesterol, HDL/LDL-cholesterol, TG, and serum cytokines are evaluated at week 0,2,6,15(primary end-point),23(end).